Bicara Therapeutics Inc.
BCAX
$11.32
-$0.52-4.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 25.67% | -75.82% | -19.88% | -2.53% | -36.30% |
| Total Depreciation and Amortization | 0.00% | 26.67% | 0.00% | 15.38% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.18% | 23.55% | 38.40% | 90.13% | -8.91% |
| Change in Net Operating Assets | -137.57% | 142.78% | -545.93% | -161.41% | 191.53% |
| Cash from Operations | 8.94% | 6.41% | -74.36% | -33.44% | 11.51% |
| Capital Expenditure | -- | -- | -400.00% | 57.89% | -375.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -400.00% | 57.89% | -132.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -70.65% | -- | -- | 24,978.12% | 870.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 200.00% | -- |
| Cash from Financing | -70.65% | 147.18% | -100.29% | 45,422.48% | 435.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.91% | 10.95% | -109.80% | 2,699.06% | 15.28% |